Is Egrifta (Tesamorelin) Legal in Wisconsin?

Federal Legal Status of Tesamorelin

Tesamorelin is a legal, FDA-approved prescription drug in the United States. The FDA granted approval in November 2010 under the brand name Egrifta for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. A second formulation, Egrifta SV (tesamorelin 2 mg/vial), received approval in 2019.

Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue. It is not a DEA-scheduled controlled substance under the Controlled Substances Act. This matters practically: prescribers do not need a DEA-specific registration tier to prescribe it, and pharmacies do not apply Schedule II, V dispensing controls.

What the FDA Approval Actually Covers

The approved indication is narrow: reduction of excess abdominal fat in HIV-1-infected adults with lipodystrophy. The FDA label for Egrifta SV specifies 2 mg subcutaneous once daily. Off-label use (e.g., for non-HIV-related visceral obesity or growth hormone deficiency in other populations) is not prohibited by federal law, but it does affect how the drug may be compounded and reimbursed.

Clinical Evidence Supporting the Approval

The key trials that supported FDA approval are worth knowing because they define the evidence base a prescriber relies on. In Falutz et al. 2010 (N=816), tesamorelin 2 mg/day reduced VAT by approximately 18% compared with placebo at 26 weeks (P<0.001). That trial was published in the New England Journal of Medicine. A separate maintenance trial showed that patients who continued tesamorelin maintained VAT reduction, while those switched to placebo regained abdominal fat within 26 weeks. The Falutz 2010 maintenance data are available on PubMed.

IGF-1 levels rose by roughly 114 mcg/L from baseline in tesamorelin-treated patients versus 5 mcg/L in the placebo arm. The FDA review of these pharmacodynamic data is publicly available.

Wisconsin State Law Framework

Wisconsin has no statute that independently schedules or bans tesamorelin. The legal analysis for a Wisconsin resident begins and ends with federal law plus the Wisconsin Pharmacy Examining Board (WPEB) rules that mirror federal compounding standards.

Wisconsin Pharmacy Examining Board Authority

The WPEB operates under Wis. Stat. Ch. 450 and Wis. Admin. Code Phar. The Board licenses pharmacies and pharmacists and adopts USP standards for compounding. A pharmacy physically located in Wisconsin must hold a WPEB license to dispense. An out-of-state pharmacy shipping to a Wisconsin patient must hold a WPEB nonresident pharmacy permit.

Medical Practice Act for Prescribers

Wisconsin prescribers are governed by Wis. Stat. Ch. 448, which requires that a valid prescriber-patient relationship exist before any prescription drug is issued. For tesamorelin, this means a licensed physician (MD or DO), nurse practitioner, or physician assistant must evaluate the patient, document a diagnosis supporting the prescription, and issue a written or electronic order. A telehealth visit satisfies this requirement under Wis. Stat. § 448.9725, provided the prescriber holds a Wisconsin license.

No State-Specific Restrictions

Unlike anabolic steroids, which Wisconsin schedules under Wis. Stat. § 961.01 as Schedule III controlled substances, tesamorelin carries no Wisconsin-specific scheduling. Prescribers do not face additional state-law hurdles beyond those that apply to any legend (prescription-only) drug.

The Compounding Question: 503A vs. 503B

This is where most patients encounter confusion. The branded drug Egrifta SV (tesamorelin 2 mg/vial, Theratechnologies) is commercially available, but some patients and clinics pursue compounded tesamorelin for cost or formulation reasons. Whether that compounding is lawful depends on which category of pharmacy is involved.

503A Traditional Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacies to compound drugs for individual patients based on a valid prescription. Key conditions include:

• The compound cannot be "essentially a copy" of a commercially available product unless there is a documented clinical difference.
• The bulk active ingredient must appear on the FDA's 503A bulks list, OR the compounded preparation must meet the "essentially a copy" exemption analysis.

Tesamorelin is not on the FDA 503A bulks list. This creates a meaningful legal question: a 503A pharmacy compounding tesamorelin from bulk powder could be producing an "essentially a copy" of Egrifta without an approved bulks-list basis. The FDA has not issued an enforcement guidance specifically naming tesamorelin as prohibited under 503A, but the regulatory risk is real. Patients obtaining compounded tesamorelin from a 503A pharmacy should confirm with their prescriber that the pharmacy has done this analysis and documented a clinical rationale (e.g., a different concentration, a diluent the patient requires, or a patient allergy to an excipient in the branded product).

The FDA guidance on 503A essentially-a-copy determinations is the operative document prescribers and pharmacies rely on.

503B Outsourcing Facilities

Section 503B outsourcing facilities may compound large batches without patient-specific prescriptions, but they must register with the FDA and comply with current Good Manufacturing Practice (cGMP). The FDA maintains a public list of registered 503B facilities. A 503B facility may supply tesamorelin preparations to a physician clinic for office administration, but 503B-compounded product cannot be sold directly to patients at retail. A Wisconsin clinic receiving 503B-compounded tesamorelin for in-office administration is operating within the law; shipping it to patients at home is not the intended pathway under 503B.

Practical Implication for Wisconsin Patients

Most Wisconsin patients who access tesamorelin legally do so in one of two ways. First, they receive branded Egrifta SV through a specialty pharmacy with a valid prescription. Second, they receive a 503A-compounded preparation where the prescribing clinician has documented a specific clinical reason the compounded version is needed. The FDA's compounding oversight page provides further detail on both pathways.

How to Get a Legal Tesamorelin Prescription in Wisconsin

Getting tesamorelin legally in Wisconsin requires three things: a qualifying clinical picture, a licensed prescriber, and a licensed pharmacy.

Step 1. Establish Care with a Licensed Wisconsin Provider

Tesamorelin requires a prescription. A board-certified endocrinologist, infectious disease specialist (for HIV-lipodystrophy), or a hormone-therapy-focused primary care provider can evaluate and prescribe. Telehealth is permitted. The Wisconsin telemedicine law does not require a prior in-person visit before a telehealth prescription, but the prescriber must hold a Wisconsin license and must document a valid clinical rationale. The American Association of Clinical Endocrinology (AACE) clinical practice guidelines are commonly used by endocrinologists evaluating growth hormone axis disorders and visceral adiposity.

Step 2. Obtain the Relevant Laboratory Work

Before prescribing tesamorelin, most clinicians order a baseline IGF-1 level. The Endocrine Society's clinical practice guideline on growth hormone deficiency recommends IGF-1 measurement as a standard diagnostic step. That guideline is accessible through the Journal of Clinical Endocrinology and Metabolism. A fasting glucose and HbA1c are also standard, because tesamorelin can cause glucose intolerance. The Egrifta SV prescribing information warns that patients with active malignancy or diabetic retinopathy are contraindicated.

Step 3. Choose a Licensed Dispensing Pharmacy

Options in Wisconsin include:

• In-state licensed pharmacies holding a WPEB license that compound or dispense tesamorelin.
• Specialty pharmacies (e.g., those contracted with Theratechnologies for Egrifta SV distribution).
• WPEB nonresident-permit pharmacies shipping from out of state.

The WPEB nonresident pharmacy permit database is searchable through the Wisconsin Department of Safety and Professional Services license lookup.

Telehealth Access Specifically

Wisconsin Statute § 448.9725 defines "telemedicine" and establishes that a telemedicine encounter can satisfy the prescriber-patient relationship requirement. A Wisconsin-licensed provider at a platform like HealthRX may evaluate a patient via synchronous video, review labs, and issue a tesamorelin prescription without an in-person visit. The prescription must be transmitted to a licensed pharmacy; the provider cannot dispense directly.

Monitoring and Safety Obligations After Starting Tesamorelin

Legal access does not end at the prescription pad. Continued legal and safe use requires ongoing monitoring.

IGF-1 Monitoring

The FDA label recommends checking IGF-1 at 6 months after initiation and periodically thereafter. IGF-1 above the age- and sex-adjusted upper limit of normal should prompt dose reduction or discontinuation. In the Falutz 2010 trial, 6.6% of tesamorelin-treated patients had IGF-1 values above the upper limit of normal at week 26, versus 1.5% in the placebo group. The full safety data are reported in the NEJM publication.

Glucose Monitoring

Tesamorelin raises IGF-1 and can reduce insulin sensitivity. A 2014 analysis published in Clinical Infectious Diseases found that tesamorelin-treated patients with HIV had small but statistically detectable increases in fasting glucose compared with placebo. Patients with pre-existing impaired fasting glucose should have HbA1c checked at 3 months after initiation.

Injection Site and General Safety

Subcutaneous injection at the abdomen is the required route. Lipohypertrophy at the injection site has been reported with long-term use. Rotating sites and using proper aseptic technique reduce this risk. The FDA MedWatch program accepts reports of adverse events for any FDA-approved drug including Egrifta.

What "Off-Label" Use Means Legally in Wisconsin

Physicians in Wisconsin may prescribe tesamorelin off-label. Off-label prescribing is legal under both federal law and Wisconsin medical practice standards. The FDA's guidance on off-label use states explicitly that the agency does not regulate the practice of medicine and does not prohibit prescribers from using approved drugs for unapproved indications. Wisconsin Medical Examining Board rules do not independently restrict off-label prescribing, provided the prescriber documents medical necessity and obtains informed consent.

Off-label tesamorelin use (for example, in non-HIV visceral obesity or age-related growth hormone decline) does affect insurance coverage: most commercial plans and Medicare will not cover Egrifta for non-approved indications. Patients should plan for out-of-pocket costs if pursuing tesamorelin for an off-label reason.

The HealthRX clinical team uses a three-gate framework for evaluating tesamorelin requests in Wisconsin: (1) Does the patient have a documented indication, either FDA-approved or off-label with a defensible rationale? (2) Have baseline labs (IGF-1, fasting glucose, HbA1c) been completed within 90 days? (3) Has a licensed Wisconsin pharmacy been identified that can legally dispense the prescribed formulation? All three gates must clear before a prescription is issued.

Insurance Coverage and Cost in Wisconsin

Egrifta SV is expensive. Without insurance, the list price approaches $7,000 to $10,000 per month for the branded product. Medicaid in Wisconsin covers Egrifta for its FDA-approved indication (HIV-associated lipodystrophy) subject to prior authorization. CMS Medicaid drug coverage policy guidance requires states to cover FDA-approved drugs for their approved indications when the drug is on the Medicaid national drug rebate list.

Commercial plans vary. Patients with HIV may access the Theratechnologies patient assistance program. Out-of-pocket costs for compounded tesamorelin through a 503A pharmacy are substantially lower, often in the range of $150 to $400 per month, but patients carry the regulatory risk described in the 503A section above.

Summary of Legal Pathways at a Glance

| Pathway | Legal? | Notes | |---|---|---| | Branded Egrifta SV via specialty pharmacy | Yes | Requires valid prescription; FDA-approved | | 503A compounded tesamorelin with documented clinical rationale | Conditionally yes | "Essentially a copy" analysis required; prescriber should document | | 503B outsourcing facility to clinic (office use) | Yes | Not for direct patient retail shipment | | Tesamorelin from unregistered online vendor | No | Violates FDCA; no quality or safety assurance | | Telehealth prescription (WI-licensed provider) | Yes | Wis. Stat. § 448.9725 applies |